How can the aquaculture industry lead the way to responsible use of antibiotics without sacrificing food safety and endangering human health? That question was posed recently by The Fish Site, published by U.K.-based agricultural data provider 5m.
Just as the dust is settling after the big rollout of doctor-payment data in the U.S., a new round has made its debut--in Japan. According to The Japan News, the country's top 10 drugmakers shelled out 190 billion yen ($1.66 billion) to doctors in fiscal 2013 in the form of research payments, speaking fees, entertainment, medical seminars and the like.
After crunching the data on Intercept's clinical study of OCA for nonalcoholic steatohepatitis, investigators say they tracked some distinct improvements for patients suffering from the liver disease. But they also fretted about some troubling safety issues as well as inadequate efficacy endpoints that will have to be carefully considered in follow-up studies, tempering some of the high excitement that has been stoked by some analysts and the biotech's investors ahead of a pivotal Phase III study.
When it comes to cattle feed additive Zilmax, pulled from the market last year on concerning side-effect reports, there's nothing to worry about, Merck says. After a comprehensive review, the drugmaker has determined the product is safe when used according to its label. Now it just has to convince the meat-packing industry.
That scary $9 billion damages award a Louisiana jury slapped on Takeda and Eli Lilly earlier this year? A U.S. district judge slashed the bill by more than 99%, saying the new amount is the biggest award allowed under current law.
When Parkinson's disease patients start taking new meds, doctors go on the lookout for the usual side effects: dizziness, nausea, and the like. But according to a new study, they need to think weird, too. The risk of compulsive behavior--gambling, shopping, sex--is much higher than previously thought.
The problem of contaminated cold remedies has once again surfaced in the U.S. More than seven years after diethylene glycol put authorities on high alert, a toddler in New York has suffered from lead poisoning after taking a Chinese cold remedy.
It was way back in 2009 when the FDA first indicated it was worried about reports of heart attacks and strokes in patients taking Xolair, the asthma treatment co-marketed by Novartis and Roche. Now the agency is taking action, slapping new warnings to the product's label confirming that it's associated with cardiovascular risks.
The FDA polished up the official label on Pfizer's stop-smoking drug Chantix earlier this week. It was a victory for Pfizer, the payoff from several studies testing the drug for psychiatric side effects. Essentially, the new label will include study data suggesting that patients using the drug might not be at a greater risk of psychiatric problems after all.
Eye drug delivery outfit Novaliq touted a positive Phase I for its cyclosporin eye drops designed to treat dry eye disease. Novaliq's semifluorinated alkane technology allows for a clear solution of cyclosporin, which is poorly soluble in water, thus making for a more effective eye drop that doesn't impair vision, the company says.